Eli Lilly (LLY) Acquisitions (2010 - 2022)

Eli Lilly (LLY) has reported Acquisitions for 11 consecutive years, with $327.2 million the latest figure, recorded in Q4 2022.

• Acquisitions for Q4 2022 came in at $327.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $327.2 million (down 56.22% YoY), and the FY2022 annual result was $327.2 million, down 56.22% from the prior year.
• Acquisitions was $327.2 million for Q4 2022 at Eli Lilly, down from $747.4 million in the prior quarter.
• Over five years, Acquisitions peaked at $6.9 billion in Q1 2019 and troughed at $327.2 million in Q4 2022.
• Average Acquisitions over 4 years is $2.2 billion, with a median of $798.3 million recorded in 2020.
• Year-over-year, Acquisitions tumbled 87.72% in 2020 and declined 12.0% in 2021.
• Over 4 years, Acquisitions stood at $6.9 billion in 2019, then sank by 87.72% to $849.3 million in 2020, then declined by 12.0% to $747.4 million in 2021, then tumbled by 56.22% to $327.2 million in 2022.
• Per Business Quant data, the three most recent Acquisitions figures were $327.2 million in Q4 2022, $747.4 million in Q1 2021, and $849.3 million in Q1 2020.